Labcorp to offer FDA-cleared Elecsys pTau-217 Alzheimer's test

0 min read | Published on 24 Aug 2026, 04:52 PM |Updated on 24 Aug 2026, 04:52 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Labcorp to offer Elecsys pTau-217 test after FDA clearance
First single-biomarker blood test to rule in/out amyloid pathology
Measures phosphorylated Tau 217, a hallmark of Alzheimer's disease
Intended for patients aged 55+ with cognitive decline signs

*this image is generated using AI for illustrative purposes only.

Labcorp (NYSE: LH) announced it will offer the Elecsys pTau-217 blood test following clearance by the U.S. Food and Drug Administration. The test aids in identifying amyloid pathology associated with Alzheimer's disease.

The assay measures phosphorylated Tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer's disease. Developed by Roche Diagnostics, the test is intended for individuals aged 55 and older who exhibit signs, symptoms, or complaints of cognitive decline.

Regulatory Status

Elecsys pTau-217 holds the distinction of being the first and only FDA-cleared single-biomarker blood test capable of both ruling in and ruling out amyloid pathology. This clearance applies across both specialty and primary care settings.

What the Numbers Show

The regulatory approval establishes a unique market position for the test as the sole single-biomarker option cleared for dual diagnostic utility (ruling in and out) in this category. This differentiates it from multi-biomarker or non-cleared alternatives currently available in the market.

How might the integration of Elecsys pTau-217 into primary care settings impact Labcorp's revenue streams and patient volume compared to specialty care channels?

What is the potential impact on Roche Diagnostics' licensing or partnership revenue given their role in developing the assay cleared for Labcorp?

How will competitors like Quest Diagnostics or emerging biotech firms respond to Labcorp's exclusive access to this FDA-cleared single-biomarker test in the short term?

Baird raises Labcorp Holdings target to $338

0 min read | Published on 14 Jul 2026, 01:42 AM |Updated on 14 Jul 2026, 01:42 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Baird analyst Eric Coldwell maintained an Outperform rating on Labcorp Holdings, raising the price target to $338 from $335. Separately, B of A Securities analyst Michael Ryskin maintained a Buy rating with a price target of $320, up from $300.

*this image is generated using AI for illustrative purposes only.

Baird analyst Eric Coldwell has maintained an Outperform rating on Labcorp Holdings while raising the price target to $338 from $335. This adjustment signals increased confidence in the company's performance potential. Separately, B of A Securities analyst Michael Ryskin has maintained a Buy rating on the stock with a price target of $320, up from $300.

Rating and Target Details

The revised price target of $338 from Baird represents an increase from the previous target of $335. The Outperform rating remains unchanged, indicating a continued positive outlook on the stock.